Figure 1. The schedule of treatment and imaging tests.

Schematic of combination treatment for patients with advanced or metastatic breast cancer. All patients received bevacizumab (5 mg/kg body weight) intravenously on days 1 and 15 in combination with paclitaxel (80 mg/m² body surface area) on days 1, 8, and 15 and repeated every 4 weeks. Subsequently, the patients underwent 5 additional cycles of bevacizumab and paclitaxel. Both before treatment and after the 2^nd cycle of chemotherapy, the patients underwent MRI, FDG-PET/CT, and FMISO-PET/CT. Imaging using diffuse optical spectroscopy was also performed on day 1 before the first infusion of bevacizumab and on days 1, 3, 6, 8, and 13 after the infusion.